Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03827447 · ClinicalTrials.gov registry record · Phase 1

Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile

A Phase 1 study of Clostridium Difficile Infection, sponsored by Medical College of Wisconsin.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target
1
Study location

NCT03827447 is a Phase 1 study of Clostridium Difficile Infection that has completed, run by Medical College of Wisconsin. The registered enrollment target is 7 participants, below the 12,065-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03827447, a Phase 1 study of Clostridium Difficile Infection, has completed, sponsored by Medical College of Wisconsin.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This study proposes to: 1. Characterize the impact of oral vancomycin on C. difficile loads after end of treatment compared to a placebo group. 2. Determine the effect of oral vancomycin on structural and functional microbiome changes after end of treatment compared to a placebo group. 3. Characterize the impact of oral vancomycin against a placebo group on the daily frequency of loose stools by the end of treatment.

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG Vancomycin Oral Capsule

Study Locations (1)

Wisconsin

  • Medical College of Wisconsin, Inc. - Milwaukee

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2019-07-17
Est. Completion 2021-06-30
Phase Phase 1

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT03827447

The ClinicalTrials.gov registry entry for NCT03827447 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,065-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (100% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.

NCT03827447 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03827447 about?

NCT03827447 is a clinical study titled "Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile". This study proposes to: 1. Characterize the impact of oral vancomycin on C. difficile loads after end of treatment compared to a placebo group. 2. Determine the effect of oral vancomycin on structural and functional microbiome changes after end of treatment compared to a placebo group. 3. Character...

What is the current status of trial NCT03827447?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-07-17. Estimated completion is 2021-06-30.

What conditions does trial NCT03827447 study?

This clinical trial studies the following conditions: Clostridium Difficile Infection.

What interventions are being tested in trial NCT03827447?

The interventions under investigation include: Placebo Oral Capsule (DRUG), Vancomycin Oral Capsule (DRUG).

Who is sponsoring clinical trial NCT03827447?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03827447 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Clostridium Difficile Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.